株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

感染症治療:世界市場

Global Markets for Infectious Disease Treatments

発行 BCC Research 商品コード 117624
出版日 ページ情報 英文 315 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.57円で換算しております。
Back to Top
感染症治療:世界市場 Global Markets for Infectious Disease Treatments
出版日: 2018年03月01日 ページ情報: 英文 315 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の感染症治療市場規模は、2017年に648億米ドルとなりました。同市場は2017年から2022年にかけて8.9%のCAGR (年間複合成長率) で推移し、2022年までに990億米ドルに達すると予測されています。

当レポートでは、世界の感染症治療市場について、新規治療法、ワクチンおよび関連製品に注目して調査し、市場実績データ・5年間のCAGR予測を含む世界市場の動向分析、抗生物質耐性物質とその人間に対する影響、技術開発・将来動向・新しい機会の調査、感染症の疾患タイプ別による現況と適切な治療法および地域別の分析、特許分析、および主要企業のプロファイルなどを提供しております。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 概要

  • 世界の主な死因
  • 感染症
  • 細菌感染症
  • ウィルス感染症
  • エボラのケーススタディ
  • 原虫感染症
  • 発生・拡散の原因
  • ワクチン
  • 抗生物質

第4章 疾病の概要

  • B型・C型肝炎
  • 単純ヘルペスウイルス
  • HIV/AIDS
  • A型・B型インフルエンザ
  • ロタウィルス
  • RSウイルス (呼吸器合胞体ウイルス)
  • マラリア
  • 結核
  • 東呼吸器症候群コロナウイルス (MERS-CoV)
  • ウイルス性出血性熱:ラッサ熱
  • ウイルス性出血性熱:エボラ熱
  • ウイルス性出血性熱:マールブルグ熱
  • ウイルス性出血性熱:ジカ熱
  • ウイルス性出血性熱:黄熱病
  • ウイルス性出血性熱:デング熱

第5章 感染症治療:市場・予測

  • 世界の感染症治療薬
  • 世界の感染症

第6章 感染症治療:市場ダイナミクス

  • 感染症
  • B型肝炎
  • C型肝炎
  • ヘルペス
  • HIV/AIDS
  • A型・B型インフルエンザ
  • ロタウィルス
  • RSウィルス
  • マラリア
  • 結核
  • 東呼吸器症候群コロナウイルス (MERS-CoV)
  • ウイルス性出血性熱:ラッサ熱
  • ウイルス性出血性熱:エボラ熱
  • ウイルス性出血性熱:マールブルグ熱
  • ウイルス性出血性熱:ジカ熱
  • ウイルス性出血性熱:黄熱病
  • ウイルス性出血性熱:デング熱

第7章 抗生物質耐性

  • 概要
  • 抗生物質耐性のメカニズム
  • 抗生物質耐性の理由

第8章 感染症治療:研究・開発 (R&D)

  • 概要
  • B型肝炎・C型肝炎
  • 単純ヘルペス
  • HIV/AIDS
  • A型・B型インフルエンザ
  • ロタウィルス
  • RSウィルス
  • マラリア
  • 結核
  • MERS-CoV
  • ウイルス性出血性熱

第9章 感染症治療:次世代の予測ツール

  • 概要
  • なぜツールを予測する必要があるのか?
  • 実例:感染症モデリングにおけるツール
  • 実例:感染症モデリングにおけるモバイルアプリケーション
  • 感染症モデリングにおける現在の限界

第10章 感染症治療:特許分析

  • B型肝炎
  • C型肝炎
  • 単純ヘルペスウィルス
  • HIV/AIDS
  • インフルエンザ
  • ロタウィルス
  • RSウィルス
  • マラリア
  • 結核
  • 東呼吸器症候群コロナウイルス (MERS-CoV)
  • ウイルス性出血性熱:ラッサ熱
  • ウイルス性出血性熱:エボラ熱
  • ウイルス性出血性熱:マールブルグ熱
  • ウイルス性出血性熱:ジカ熱
  • ウイルス性出血性熱:デング熱
  • ウイルス性出血性熱:黄熱病

第11章 企業プロファイル

付録

BCC Researchについて

目次
Product Code: PHM061D

Report Highlights

The global market for infectious disease treatments totaled $64.8 billion in 2017. The market should total $99 billion by 2022, growing at a compound annual growth rate (CAGR) of 8.9% from 2017 to 2022.

Report Includes:

  • 84 data tables and 23 additional tables
  • An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical treatments, vaccines, and environmental products
  • Analyses of global market trends with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Discussion of the increasing concerns regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans
  • Examination of technological developments, future trends, and emerging opportunities
  • Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by region
  • Patent analyses
  • Company profiles of major players in the market, including Alere (now Abbott), Novartis, Roche Diagnostics, Sanofi Pasteur and Siemens Healthineers

Report Scope

The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals and diagnostic kits, recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of non-branded generics.

BCC Research has categorized the markets based on regions defined by the WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships in a large number of infectious diseases. Regions include Africa, Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific. These cover all the WHO participating countries, which are described in detail in the subsequent section.

Analyst Credentials

Ms. Joshi has a master's degree in biotechnology from the Indian Institute of Technology (I.I.T), Mumbai, and a diploma in management consulting from the Consultancy Development Centre, DSIR, Ministry of Science and Technology, India. She has eight years of research experience in competitive intelligence, technology strategy and market analysis in the pharmaceuticals, biotechnology and agrochemical industries.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Overview

  • Top Global Causes of Death
  • Infectious Diseases
    • Classification of Infectious Agents
    • Classification of Modes of Transmission
    • Management of Infectious Diseases
  • Bacterial Infectious Diseases
  • Viral Infectious Diseases
  • Ebola Case Study
    • Magnitude of the Outbreak
    • Response to Manage Ebola
    • Reasons for Rapid Spread of the Disease
    • Current Outlook and Advisory
  • Protozoan Infectious Diseases
  • Factors Responsible for Emergence and Spread
  • Vaccines
  • Antibiotics
    • Mechanism of Action

Chapter 4: Disease Overview

  • Hepatitis B and Hepatitis C
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment
  • Herpes Simplex Virus
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment
  • HIV/AIDS
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment
  • Influenza A and Influenza B
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment
  • Rotavirus
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment
  • Respiratory Syncytial Virus
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment
  • Malaria
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment
  • Tuberculosis
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment
  • Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment
  • Viral Hemorrhagic Fevers-Lassa Fever
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
  • Viral Hemorrhagic Fevers-Ebola Fever
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment
  • Viral Hemorrhagic Fevers-Marburg
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment
  • Viral Hemorrhagic Fevers-Zika Virus
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment
  • Viral Hemorrhagic Fevers-Yellow Fever
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment
  • Viral Hemorrhagic Fevers-Dengue
    • Incidence and Geographical Distribution
    • Risk Factors
    • Etiology and Symptoms
    • Socio-Economic Burden
    • Diagnosis
    • Treatment

Chapter 5: Markets and Forecast

  • Global Market for Infectious Disease Treatments
    • Global Market for Infectious Disease Treatments by Region
    • Global Market for Infectious Disease Therapeutics by Disease Type
    • Global Market for Infectious Disease Vaccines by Disease Type
    • Global Market for Infectious Disease Diagnostics by Disease Type
  • Global Infectious Diseases
    • Hepatitis B and Hepatitis C
    • Herpes Simplex Virus
    • HIV/AIDS
    • Influenza - A, B
    • Rotavirus
    • Respiratory Syncytial Virus
    • Malaria
    • Tuberculosis
    • MERS-CoV
    • Viral Hemorrhagic Fevers

Chapter 6: Market Dynamics

  • Infectious Diseases
    • Drivers
    • Deterrents
    • Unmet Needs
  • Hepatitis B
    • Drivers
    • Deterrents
    • Unmet Needs
  • Hepatitis C
    • Drivers
    • Deterrents
    • Unmet Needs
  • Herpes
    • Drivers
    • Deterrents
    • Unmet Needs
  • HIV/AIDS
    • Drivers
    • Deterrents
    • Unmet Needs
  • Influenza A&B
    • Drivers
    • Deterrents
    • Unmet Needs
  • Rotavirus
    • Drivers
    • Deterrents
    • Unmet Needs
  • Respiratory Syncytial Virus
    • Drivers
    • Deterrents
    • Unmet Needs
  • Malaria
    • Drivers
    • Deterrents
    • Unmet Needs
  • Tuberculosis
    • Drivers
    • Deterrents
    • Unmet Needs
  • MERS-CoV
    • Drivers
    • Deterrents
    • Unmet Needs
  • Viral Hemorrhagic Fevers-Lassa
    • Drivers
    • Deterrents
    • Unmet Needs
  • Viral Hemorrhagic Fevers-Ebola
    • Drivers
    • Deterrents
    • Unmet Needs
  • Viral Hemorrhagic Fevers-Marburg
    • Drivers
    • Deterrents
    • Unmet Needs
  • Viral Hemorrhagic Fevers-Zika
    • Drivers
    • Deterrents
    • Unmet Needs
  • Viral Hemorrhagic Fevers-Yellow Fever
    • Drivers
    • Deterrents
    • Unmet Needs
  • Viral Hemorrhagic Fevers-Dengue
    • Drivers
    • Deterrents
    • Unmet Needs

Chapter 7: Antibiotic Resistance

  • Overview
  • Mechanisms of Antibiotic Resistance
  • Reasons for Antibiotic Resistance
    • Antibiotic Resistance-Incidence
    • New Antibiotics in Development

Chapter 8: Research and Development

  • Overview
  • Hepatitis B and Hepatitis C
  • Herpes Simplex Virus
  • HIV/AIDS
  • Influenza A and Influenza B
  • Rotavirus
  • Respiratory Syncytial Virus
  • Malaria
  • Tuberculosis
  • MERS
  • Hemorrhagic Fevers
    • Dengue
    • Ebola
    • Lassa fever
    • Marburg
    • Yellow Fever
    • Zika

Chapter 9: Next Generation Predictive Tools

  • Overview
  • Why Do We Need Forecast Tools?
  • Examples - Tools in Infectious Disease Modeling
  • Examples - Mobile Apps in Infectious Disease Modeling
  • Current Limitations in Infectious Disease Modeling

Chapter 10: Patent Analysis

  • Hepatitis B
    • Key Patent Publications
  • Hepatitis C
    • Key Patent Publications
  • Herpes Simplex Virus
    • Key Patent Publications
  • HIV/AIDS
    • Key Patent Publications
  • Influenza
    • Key Patent Publications
  • Rotavirus
    • Key Patent Publications
  • Respiratory Syncytial Virus
    • Key Patent Publications
  • Malaria
    • Key Patent Publications
  • Tuberculosis
    • Key Patent Publications
  • MERS-CoV
    • Key Patent Publications
  • Viral Hemorrhagic Fevers-Lassa
    • Key Patent Publications
  • Viral Hemorrhagic Fevers-Ebola
    • Key Patent Publications
  • Viral Hemorrhagic Fevers-Marburg
    • Key Patent Publications
  • Viral Hemorrhagic Fevers-Zika
    • Key Patent Publications
  • Viral Hemorrhagic Fevers-Dengue
    • Key Patent Publications
  • Viral Hemorrhagic Fevers-Yellow Fever
    • Key Patent Publications

Chapter 11: Company Profiles

Appendix

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table: Global Market for Infectious Diseases, by Segment, Through 2022 ($ Millions)
    • Table 1: Global Health Estimates, Leading Causes of Death, by WHO Region, 2015 (Number)
    • Table 2: Global Health Estimates, Leading Causes of Death, Infectious Diseases, by WHO Region, 2015 (Number)
    • Table 3: Reported Cases and Deaths in Ebola Outbreaks, 2007-2016 (Number)
    • Table 4: Prevalence and Incidence of Hepatitis B, 2015 (Number)
    • Table 5: Prevalence and Incidence of Hepatitis C, 2015 (Number)
    • Table 6: Global Death Rate Related to Hepatitis B, 1990-2015 (Rate per 100,000)
    • Table 7: Global Death Rate Related to Hepatitis C, 1990-2015 (Rate per 100,000)
    • Table 8: Global Prevalence and Incidence of Genital Herpes (Number)
    • Table 9: Prevalence of HIV, Adults (15-49 years old), by WHO Region, 2015 (%)
    • Table 10: New HIV Infections (per 1,000 uninfected population), Adults (15-49 years old), by WHO Region, 2015 (Number per 1,000)
    • Table 11: New HIV Infections, 2000-2030
    • Table 12: HIV/AIDS Related Deaths, 2000-2030
    • Table 13: Years of Life Lost (YLLs), Pandemic Influenza A, H1N1, by WHO Region, 2009 (Number)
    • Table 14: Estimates of Incidence and Number of New Cases, RSV-Associated ALRI and Severe ALRI, Children Under 5 Years, January 1995-June 2009
    • Table 15: Hospitalization Rates, RSV-Infected Babies, 1950-2006 (Review*) (Per 1,000)
    • Table 16: Estimated Malaria Incidence, by WHO Region, 2000-2015 (Per 1,000 at Risk)
    • Table 17: Suspected Malaria Cases, by WHO Region, 2010-2015 (Millions)
    • Table 18: Confirmed Malaria Cases, by WHO Region, 2010-2015 (Millions)
    • Table 19: Estimated Spending on Malaria Treatment, Sub-Saharan Africa, 2010-2014 ($ Millions)
    • Table 20: WHO Guidelines for Treatment of Malaria
    • Table 21: Treatment Regimen, Drug Susceptible TB
    • Table 22: MERS-CoV Outbreak Updates by WHO, Global, January 2016-June 13, 2017 (Number)
    • Table 23: Laboratory Test for MERS CoV, Recommendation by WHO
    • Table 24: Lassa Fever Outbreak Updates by WHO, Global, January 2006-March 2017 (Number)
    • Table 25: Reported Cases and Deaths in Ebola Outbreaks, 2007-June 2017
    • Table 26: Reported Cases and Deaths in Marburg Virus, 1998-June 2017
    • Table 27: Zika Outbreak Burden, 2015-2016
    • Table 28: Reported Cases and Deaths, Yellow Fever, 2010-April 2017
    • Table 29: Disease Burden-Yellow Fever in Africa, 2017
    • Table 30: Estimated Disease Burden-Yellow Fever in Africa, 1995-2013 (Number/Years)
    • Table 31: Global Prevalence and Incidence of Dengue, 2015
    • Table 32: Global Market for Infectious Disease Treatment, by Region, Through 2022 ($ Millions)
    • Table 33: Global Market for Infectious Disease Therapeutics, by Disease Type, Through 2022 ($ Millions)
    • Table 34: Global Market for Infectious Disease Vaccines, by Disease Type, Through 2022 ($ Millions)
    • Table 35: Global Market for Infectious Disease Diagnostics, by Disease Type, Through 2022 ($ Millions)
    • Table 36: Global Market Share for Hepatitis B Drugs, by Brand, 2016 (%)
    • Table 37: Global Market for Hepatitis B Therapeutics, by WHO Region, Through 2022 ($ Millions)
    • Table 38: Global Market for Hepatitis B Vaccines, by WHO Region, Through 2022 ($ Millions)
    • Table 39: Global Market for Hepatitis B Diagnostics, by WHO Region, Through 2022 ($ Millions)
    • Table 40: Global Market Share for Hepatitis C Drugs, by Brand, 2016 (%)
    • Table 41: Global Market for Hepatitis C Therapeutics, by WHO Region, Through 2022 ($ Millions)
    • Table 42: Global Market for Hepatitis C Diagnostics, by WHO Region, Through 2022 ($ Millions)
    • Table 43: Global Market for HSV Therapeutics, by WHO Region, Through 2022 ($ Millions)
    • Table 44: Global Market for HSV Diagnostics, by WHO Region, Through 2022 ($ Millions)
    • Table 45: Global Market Share for HIV Drugs, by Brand, 2016 (%)
    • Table 46: Global Market for HIV Therapeutics, by WHO Region, Through 2022 ($ Millions)
    • Table 47: Global Market for HIV Diagnostics, by WHO Region, Through 2022 ($ Millions)
    • Table 48: Global Market Share for Influenza Vaccines, by Brand, 2016 (%)
    • Table 49: Global Market Share for Influenza (Antivirals), by Brand, 2016 (%)
    • Table 50: Global Market for Influenza Vaccines, by WHO Region, Through 2022 ($ Millions)
    • Table 51: Global Market for Influenza Diagnostics, by WHO Region, Through 2022 ($ Millions)
    • Table 52: Global Market Share for Rotavirus Vaccines, by Brand, 2016 (%)
    • Table 53: Global Market for Rotavirus Vaccines, by WHO Region, Through 2022 ($ Millions)
    • Table 54: Global Market for Rotavirus Diagnostics, by WHO Region, Through 2022 ($ Millions)
    • Table 55: Global Market for RSV Vaccines, by WHO Region, Through 2022 ($ Millions)
    • Table 56: Global Market for RSV Diagnostics, by WHO Region, Through 2022 ($ Millions)
    • Table 57: Global Market Share for ACTs, by Active Ingredient, 2016 (%)
    • Table 58: Global Market for Malaria Therapeutics, by WHO Region, Through 2022 ($ Millions)
    • Table 59: Global Market for Malaria Vaccines, by Region, Through 2022 ($ Millions)
    • Table 60: Global Market for Malaria Diagnostics (RDTs*), by WHO Region, Through 2022 ($ Millions)
    • Table 61: Global Market for Tuberculosis Therapeutics, by WHO Region, Through 2022 ($ Millions)
    • Table 62: Global Market for Tuberculosis Diagnostics, by WHO Region, Through 2022 ($ Millions)
    • Table 63: Global Market for MERS-CoV Vaccines, by WHO Region, Through 2022 ($ Millions)
    • Table 64: Global Market for Lassa Fever Vaccines, by WHO Region, Through 2022 ($ Millions)
    • Table 65: Global Market for Ebola Fever Vaccines, Through 2022 ($ Millions)
    • Table 66: Global Market for Zika Vaccines, by WHO Region, Through 2022 ($ Millions)
    • Table 67: Global Market for Yellow Fever Vaccines, by WHO Region, Through 2022 ($ Millions)
    • Table 68: Global Market for Dengue Vaccines, by WHO Region, Through 2022 ($ Millions)
    • Table 69: Reported Range of Resistant Population Proportion (%), by WHO Region (%)
    • Table 70: WHO Priority List, Pathogens for R&D of New Antibiotics
    • Table 71: Global Antibiotics Development Pipeline
    • Table 72: Hepatitis B and Hepatitis C Development Pipeline and Recent Launches
    • Table 73: Herpes Simplex Virus Development Pipeline and Recent Launches
    • Table 74: HIV/AIDS Development Pipeline and Recent Launches
    • Table 75: Influenza A and Influenza B Development Pipeline and Recent Launches
    • Table 76: Rotavirus Development Pipeline and Recent Launches
    • Table 77: RSV Development Pipeline and Recent Launches
    • Table 78: Malaria Development Pipeline and Recent Launches
    • Table 79: Tuberculosis Development Pipeline and Recent Launches
    • Table 80: MERS Development Pipeline and Recent Launches
    • Table 81: Dengue Development Pipeline and Recent Launches
    • Table 82: Ebola Development Pipeline and Recent Launches
    • Table 83: Lassa Fever Development Pipeline and Recent Launches
    • Table 84: Marburg Development Pipeline and Recent Launches
    • Table 85: Yellow Fever Development Pipeline and Recent Launches
    • Table 86: Zika Development Pipeline and Recent Launches
    • Table 87: Hepatitis B Published Patent Applications, 2013-2017
    • Table 88: Hepatitis C Published Patent Applications, 2013-2017
    • Table 89: Herpes Simplex Virus Published Patent Applications, 2013-2017
    • Table 90: HIV/AIDS Published Patent Applications, 2013-2017
    • Table 91: Influenza Published Patent Applications, 2013-2017
    • Table 92: Rotavirus Published Patent Applications, 2013-2017
    • Table 93: Respiratory Syncytial Virus Published Patent Applications, 2013-2017
    • Table 94: Malaria Published Patent Applications, 2013-2017
    • Table 95: Tuberculosis Published Patent Applications, 2013-2017
    • Table 96: MERS Published Patent Applications, 2013-2017
    • Table 97: Lassa Fever Published Patent Applications, 2013-2017
    • Table 98: Ebola Virus Published Patent Applications, 2013-2017
    • Table 99: Marburg Virus Published Patent Applications, 2013-2017
    • Table 100: Zika Published Patent Applications, 2013-2017
    • Table 101: Dengue Fever Published Patent Applications, 2013-2017
    • Table 102: Yellow Fever Published Patent Applications, 2013-2017
    • Table 103: Number of MMV Supported Projects, by Partner
    • Table 104: Abbreviations Used in “Global Markets for Infectious Diseases”
    • Table 105: Glossary of Terms Used in “Global Markets for Infectious Diseases”
    • Table 106: Report Sources

List of Figures

  • Summary Figure: Global Market for Infectious Diseases, by Segment, 2016-2022 ($ Millions)
    • Figure 1: Global Health Estimates, 20 Leading Causes of Death, 2015 (Thousands)
    • Figure 2: Global Health Estimates, Leading Causes of Death, by WHO Region, 2015 (Number)
    • Figure 3: Global Health Estimates, Leading Causes of Death, Infectious Diseases, by WHO Region, 2015 (Number)
    • Figure 4: Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), by Total Number Cases, March 2014-February 2016
    • Figure 5: Outbreaks in West Africa (Guinea, Liberia, Sierra Leone), Total Number of Deaths, March 2014-February 2016
    • Figure 6: Global Vaccination Coverage, by Vaccine, 2015 (%)
    • Figure 7: Global Death Rate Related to Hepatitis B, 1990-2015 (Rate per 100,000)
    • Figure 8: Years of Life (YLLs) Lost Related to Hepatitis B, Global, 2012-2015 (Number)
    • Figure 9: Global Death Rate Related to Hepatitis C, 1990-2015 (Rate per 100,000)
    • Figure 10: Years of Life (YLLs) Lost Related to Hepatitis C, Global, 2012-2015 (Number)
    • Figure 11: DALYs (Disability-affected Life Years) caused by Genital Herpes, Global, 1990-2015 (Number)
    • Figure 12: Global Market Share of New HIV Infections, by WHO Region, 2015 (%)
    • Figure 13: Global Market Share of HIV/AIDS Related Deaths, by WHO Region, 2015 (%)
    • Figure 14: Estimated Number of Deaths, 2009 Pandemic Influenza A H1N1, by WHO Region, August 2009-August 2010 (Number)
    • Figure 15: Global Infant Deaths due to Rotavirus, 2009-2013 (Number)
    • Figure 16: Countries with Highest Number of Infant Deaths due to Rotavirus, 2013 (Number)
    • Figure 17: Global Number of Malaria Caused Deaths, 2011-2015
    • Figure 18: Global Prevalence of Tuberculosis, 1990-2015 (Rate, per 100,000)
    • Figure 19: Global Incidence of Tuberculosis, 1990-2015 (Rate, per 100,000)
    • Figure 20: Global Deaths due to Tuberculosis, 1990-2015 (Rate, per 100,000)
    • Figure 21: Global Disability-Adjusted Life Years Caused by Tuberculosis, 1990-2015 (Number)
    • Figure 22: Global Incidence of Cases and Deaths from Lassa Fever, November 2015-May 2016 (Number)
    • Figure 23: Total Number of Cases due to Ebola Outbreaks in West Africa Affected Countries (Guinea, Liberia, Sierra Leone), March 2014-February 2016
    • Figure 24: Total Number of Deaths due to Ebola Outbreaks in West Africa (Guinea, Liberia, Sierra Leone), March 2014-February 2016
    • Figure 25: Number of Cases and Deaths due to Major Marburg Outbreaks, 1998-June 2017 (Number)
    • Figure 26: Number of Countries (Y) with Number of Confirmed Zika Cases (X) in the Americas Region, 2015-2016 (Number)
    • Figure 27: Global Disability-Adjusted Life Years (DALYs) due to Yellow Fever, 1990-2015 (Rate, per 100,000)
    • Figure 28: Global Death Rate caused by Yellow Fever, 1990-2015 (Rate, per 100,000)
    • Figure 29: Average Annual Number of Dengue Cases, 1960-2007
    • Figure 30: Number of Dengue Cases reported in America, 2012-2016
    • Figure 31: Incidence Rate of Dengue in Americas, 2012-2016 (per 100,000 Inhabitants)
    • Figure 32: Global Deaths caused by Dengue, 2011-2015 (Number)
    • Figure 33: Dengue Caused Years of Life Lost*, Global, 2011-2015 (Number of Years)
    • Figure 34: Global Market for Hepatitis B Therapeutics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 35: Global Market for Hepatitis B Vaccines, by WHO Region, 2016-2022 ($ Millions)
    • Figure 36: Global Market for Hepatitis B Diagnostics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 37: Global Market for Hepatitis C Therapeutics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 38: Global Market for Hepatitis C Diagnostics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 39: Global Market for HSV Therapeutics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 40: Global Market for HSV Diagnostics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 41: Global Market for HIV/AIDS Therapeutics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 42: Global Market for HIV Diagnostics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 43: Global Market for Influenza Vaccines, by WHO Region, 2016-2022 ($ Millions)
    • Figure 44: Global Market for Influenza Diagnostics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 45: Global Market for Rotavirus Vaccines, by WHO Region, 2016-2022 ($ Millions)
    • Figure 46: Global Market for Rotavirus Diagnostics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 47: Global Market for RSV Vaccines/Antibodies, by WHO Region, 2016-2022 ($ Millions)
    • Figure 48: Global Market for RSV Diagnostics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 49: Global Market for Malaria Therapeutics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 50: Global Market for Malaria Diagnostics (RDTs*), by WHO Region, 2016-2022 ($ Millions)
    • Figure 51: Global Market for Tuberculosis Therapeutics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 52: Global Market for Tuberculosis Diagnostics, by WHO Region, 2016-2022 ($ Millions)
    • Figure 53: Global Market for MERS-CoV Vaccine, by WHO Region, 2016-2022 ($ Millions)
    • Figure 54: Global Market for Lassa Fever Vaccines, by WHO Region, 2016-2022 ($ Millions)
    • Figure 55: Global Market for Zika Vaccines, by WHO Region, 2016-2022 ($ Millions)
    • Figure 56: Global Market for Yellow Fever Vaccines, by WHO Region, 2016-2022 ($ Millions)
    • Figure 57: Global Market for Dengue Vaccines, by WHO Region, 2016-2022 ($ Millions)
    • Figure 58: Antibiotic Use* by Class, Select Classes, 2000 and 2010 (Standard Units, billions)
Back to Top